4CPS-111 Clinical and economic impact of infliximab biosimilar Inflectra in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis naïve and switched patients: 5 years of follow-up

Background and importanceRheumatoid arthritis (RA), psoriatic arthritis (AP) and ankylosing spondylitis (AS) have a considerable impact on healthcare budgets.Aim and objectivesThe aim of this study was to determine the persistence, clinical and economic impact of the use of Inflectra in RA, AP and A...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2020-03, Vol.27 (Suppl 1), p.A99-A99
Main Authors: Borras, J, Gracia-Pérez, A, Valcuende Rosique, A, Castera, MDe, Rosique, JD, Abad, FJ
Format: Article
Language:English
Subjects:
Cost control
Economic impact
Immunotherapy
Monoclonal antibodies
Rheumatoid arthritis
TNF inhibitors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importanceRheumatoid arthritis (RA), psoriatic arthritis (AP) and ankylosing spondylitis (AS) have a considerable impact on healthcare budgets.Aim and objectivesThe aim of this study was to determine the persistence, clinical and economic impact of the use of Inflectra in RA, AP and AS naïve and Remicade switched patients.Material and methodsThis was an observational, retrospective cohort study of patients treated with Inflectra for more than 6 months, between June 2015 and September 2019. We collected age, sex, indication and persistence of Inflectra naïve and switched patients. Safety was also assessed. We determined the real cost of Inflectra treatment for each patient from individualised intravenous administration, and correlated dates during the study period were collected from DISPENSA (Oncopharm). We simulated the real cost for these patients if they received Remicade. Cost savings were calculated using official Spanish prices for Inflectra and Remicade.ResultsFrom June 2015 to September 2019, 62 patients (38 women; aged 52±20 years; weight 75±27 kg), 31 with AS, 18 with RA and 13 with AP were treated; 33 (53%) were naïve patients (15 AS, 13 RA, 5 AP) and 29 (47%) were Remicade pretreated patients (16 AS, 5 RA, 8 AP). By September 2019, 33 (54%) patients continued on Inflectra treatment (11 naïve patients and 22 Remicade pretreated patients) in clinical remission (DAS 28
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2020-eahpconf.212